CRC Research Update — October 15, 2026
Today's colorectal cancer research highlights
crc-research
A collection of 872 issues
KRAS and BRAF mutations drive distinct chromatin and transcriptional programs
Skip to content
The CRC Digest
KRAS and BRAF mutations drive distinct chromatin and transcriptional programs
Isogenic cell models revealed that RAS pathway mutations reconfigure chromatin accessibility and modulate WNT signaling, with elevated TCF7L2 expression in BRAF-mutant tumors independently predicting worse overall survival. (Cell Commun Signal)
This content is informational
Nomogram predicts survival in early-onset colorectal cancer using routine lab markers
Skip to content
The CRC Digest
Nomogram predicts survival in early-onset colorectal cancer using routine lab markers
A prognostic model incorporating T/N stage, tumor markers, and systemic immune-inflammation index achieved 3-year survival prediction AUCs of 0.897 in training and 0.861 in external validation cohorts of 410 patients
FGFR inhibition enhances immune checkpoint blockade in preclinical models
Skip to content
The CRC Digest
◇ RESEARCH
FGFR inhibition enhances immune checkpoint blockade in preclinical models
Combining FGFR pathway inhibition with PD-1 blockade reduced T cell exhaustion and promoted antitumor macrophage activity in microsatellite stable colorectal cancer models, with TCGA data showing high FGFR3 expression correlates with worse prognosis. (BMC
Survey finds low awareness of early-onset colorectal cancer among young adults
Skip to content
The CRC Digest
♥ LIVING WITH CRC
Survey finds low awareness of early-onset colorectal cancer among young adults
A survey of 1,000 people aged 20-44 found only 24% were aware of early-onset colorectal cancer, 29% had not heard of any symptoms, and female respondents felt less comfortable
ctDNA-guided chemotherapy strategy misses primary endpoint but reduces neurotoxicity
Skip to content
The CRC Digest
◆ TRIAL DATA
ctDNA-guided chemotherapy strategy misses primary endpoint but reduces neurotoxicity
The phase 2 PEGASUS trial in 135 patients with high-risk stage II/III colon cancer used serial ctDNA testing to guide treatment intensity; 3-year disease-free survival was 58.4% in ctDNA-positive patients versus
Fruquintinib plus TAS-102 shows activity in heavily pretreated metastatic colorectal cancer
Skip to content
The CRC Digest
◆ TRIAL DATA
Fruquintinib plus TAS-102 shows activity in heavily pretreated metastatic colorectal cancer
A phase II trial of 50 patients who had failed at least two prior therapies found median progression-free survival of 6.07 months and overall survival of 14.10 months, with
CRC Research Update — October 14, 2026
Today's colorectal cancer research highlights
Surgically treated early-onset rectal neuroendocrine neoplasms increased from 234 to 778 cases annually
Skip to content
The CRC Digest
Surgically treated early-onset rectal neuroendocrine neoplasms increased from 234 to 778 cases annually
A National Cancer Database analysis of 7,285 patients under 50 who underwent surgery for rectal neuroendocrine neoplasms found that annual cases increased from 234 in 2004 to 778 in 2023,
National survey finds provider barriers to early-onset CRC diagnosis
Skip to content
The CRC Digest
National survey finds provider barriers to early-onset CRC diagnosis
A national survey of 277 U.S. healthcare providers found that although 87% were concerned about early-onset colorectal cancer, approximately one-half reported that younger adults commonly experienced symptoms for four months or longer before seeking